COR — Cencora, Inc.

Cencora, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: $4.08, up 9% year-over-year.
• Consolidated Revenue: $85.9 billion, a 5.5% increase driven by growth in both reportable segments.
• Consolidated Gross Profit: $3 billion, up 18%, with a gross profit margin of 3.48%, an increase of 37 basis points.
• Operating Income: $1.1 billion, a 12% increase compared to the prior year.
• Net Interest Expense: $72 million, up $44 million due to debt from the RCA acquisition.
• Cash Balance: $1.8 billion, with negative adjusted free cash flow of $2.4 billion for the quarter, attributed to seasonal working capital needs.

2. Strategic Updates and Business Highlights

• Acquisition of OneOncology: Cencora completed the acquisition of OneOncology, enhancing its position in community oncology and expanding its MSO (Managed Services Organization) capabilities.
• Growth Priorities: Focus on strengthening leadership in specialty pharmaceuticals, leading with market leaders, and enhancing patient access to pharmaceuticals.
• US Healthcare Solutions Performance: Revenue increased by 5% to $76.2 billion, with strong sales in GLP-1 products and specialty sales to health systems and physicians.
• International Healthcare Solutions: Revenue grew 10% on an as-reported basis, but operating income declined 14% due to timing of manufacturer price adjustments.

3. Forward Guidance and Outlook

• Adjusted Diluted EPS Guidance: Reaffirmed at $17.45 to $17.75 for the fiscal year.
• Revenue Growth Expectations: Increased to 7% to 9%, up from 5% to 7%, reflecting strong performance across segments.
• Operating Income Growth: Expected to be 11.5% to 13.5%, raised from 8% to 10%, driven by the OneOncology acquisition and continued strong execution in the US healthcare solutions segment.

4. Bad News, Challenges, or Points of Concern

• Interest Expense Increase: Projected to rise significantly due to debt incurred from the OneOncology acquisition, with second-quarter interest expense expected to double that of Q1.
• Customer Loss Impact: The loss of a major oncology customer due to acquisition by a competitor continues to be a headwind affecting revenue growth.
• International Segment Challenges: Operating income in the international segment declined due to timing issues with manufacturer price adjustments, raising concerns about volatility in this area.

5. Notable Q&A Insights

• Operating Income Growth Concerns: Analysts questioned the deceleration in operating income growth in the US segment. Management reassured that performance remains strong, even excluding the impact of recent acquisitions.
• MSO Platform Opportunities: Discussion highlighted the potential for leveraging MSO capabilities to drive growth, particularly in clinical trials and revenue cycle management.
• Divestiture Strategy: Management emphasized a focus on growth-oriented investments and potential divestitures of non-core businesses to enhance long-term growth, although this may lead to short-term dilution.
• Market Pricing Dynamics: Management indicated that recent drug pricing policies (e.g., IRA negotiations) have not significantly impacted their pricing strategies or gross profit margins.

Overall, Cencora reported a strong start to fiscal 2026, bolstered by strategic acquisitions and solid performance in its US healthcare solutions segment, while also navigating challenges in international markets and rising interest expenses.